As a second objective, we performed immunostaining for GRtotal and GRβ on two clinical breast cancer cohorts: (1) one cohort that consisted of 194 clinical breast cancer samples to compare different molecular subtypes, and (2) a cohort of 161 TNBC samples to evaluate the association of GRtotal and GRβ on survival. This evidence concerns the gene GZMB and breast carcinoma.